Ascendis Pharma A/S announced results from a new pooled 3-year analysis of adults with hypoparathyroidism treated with TransCon® PTH (palopegteriparatide). The analysis, which combined data from the Phase 2 PaTH Forward and Phase 3 PaTHway trials, demonstrated sustained and clinically meaningful improvements in renal function, as measured by estimated glomerular filtration rate (eGFR), over three years of treatment. The results were shared during Kidney Week 2025 in a poster presentation by Dr. Elvira Gosmanova. The trials included 139 adults and assessed long-term renal outcomes and safety, including 24-hour urine calcium excretion and treatment-emergent adverse events. TransCon PTH is approved as YORVIPATH® in the United States, European Union, and European Economic Area for adults with hypoparathyroidism.